#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	15596	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2035	757.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1405	1405	C	909	C	855	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	0	.	n	.	0	T695C	SNP	695	695	T	1127	1127	C	980	C	925	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1769	1769	A	1001	A,G	952,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2403	2403	C	863	C,T	816,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2477	2477	A	881	A	827	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3029	3029	C	907	C,T	847,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29108	23S	2890	2890	99.9	23S.l15.c30.ctg.1	3626	799.9	0	HET	.	.	.	G2627A	.	2627	2627	G	3059	3059	G	950	G,A	656,220	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1850	folP	852	852	100.0	folP.l15.c4.ctg.1	1631	113.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1127	1129	AGC	181;184;185	A;G;C	173;176;177	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5086	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	144.0	1	SNP	p	S91F	0	.	.	271	273	TCC	609	611	TCC	177;177;176	T;C,T;C	170;169,1;171	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5086	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	144.0	1	SNP	p	D95N	0	.	.	283	285	GAC	621	623	GAC	171;170;170	G;A,G;C	162;160,1;161	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5086	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3522	144.0	1	SNP	p	D95G	0	.	.	283	285	GAC	621	623	GAC	171;170;170	G;A,G;C	162;160,1;161	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1652	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1349	122.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	419	421	ACC	204;205;204	A;C;C	192;198;197	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1652	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1349	122.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	434	436	CAC	197;194;197	C;A;C	190;185;192	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1652	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1349	122.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	617	619	CAC	206;207;208	C;A;C	191;192;194	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1652	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1349	122.1	1	SNP	p	G45D	0	.	.	133	135	GGC	437	439	GGC	197;193;195	G;G;C	189;187;188	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	866	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	830	102.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5254	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2973	176.1	1	SNP	p	D86N	0	.	.	256	258	GAC	539	541	GAC	196;195;194	G;A;C	185;178;183	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5254	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2973	176.1	1	SNP	p	S87I	0	.	.	259	261	AGT	542	544	AGT	196;193;193	A;G;T	187;181;178	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5254	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2973	176.1	1	SNP	p	S87R	0	.	.	259	261	AGT	542	544	AGT	196;193;193	A;G;T	187;181;178	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5254	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2973	176.1	1	SNP	p	S87W	0	.	.	259	261	AGT	542	544	AGT	196;193;193	A;G;T	187;181;178	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5254	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2973	176.1	1	SNP	p	S88P	0	.	.	262	264	TCC	545	547	TCC	191;189;188	T;C;C	177;173;176	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4186	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2475	167.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1443	1445	GGC	199;193;192	G;G;C,A	184;179;176,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1269	1271	GCA	226;229;229	G,T;C;A	207,1;213;217	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1272	1274	ATC	231;236;241	A;T;C	218;220;224	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1284	1286	GTG	240;239;238	G;T;G	225;220;223	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1284	1286	GTG	240;239;238	G;T;G	225;220;223	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1788	1790	ACC	171;170;169	A;C;C	158;158;160	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1842	1844	GCG	189;190;189	G;C;G	166;152;159	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1842	1844	GCG	189;190;189	G;C;G	166;152;159	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1965	1967	GGC	184;185;182	G;G;C	162;164;162	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1974	1976	GGC	169;169;165	G;G;C	151;151;145	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4038	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2410	166.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1992	1994	CCG	152;153;151	C,G;C;G	118,1;119;120	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5560	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3124	177.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2186	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1795	121.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	602	602	C	163	C	149	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	742	744	CTT	244;246;247	C;T;T	228;229;234	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	766	768	GGA	248;250;248	G;G;A	237;240;238	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	904	906	AGC	249;249;248	A;G;C	223;225;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	970	970	T	240	T,G	228,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	1	SNP	p	G120K	0	.	.	358	360	GGT	697	699	GGT	215;215;218	G;G;T	200;203;201	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	1	SNP	p	A121N	0	.	.	361	363	GCC	700	702	GCC	216;216;215	G;C;C	200;199;202	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3012	porB1b	1035	1035	96.01	porB1b.l15.c17.ctg.1	1536	195.4	1	SNP	p	A121D	0	.	.	361	363	GCC	700	702	GCC	216;216;215	G;C;C	200;199;202	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11740	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4913	238.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2011	2013	AAT	263;263;265	A,G;A;T	249,1;249;251	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1220	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	962	125.2	1	SNP	p	V57M	1	.	.	169	171	ATG	537	539	ATG	234;236;234	A;T;G	224;226;223	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
